Ruxolitinib: a targeted treatment option for patients with polycythemia vera

@inproceedings{Vaddi2016RuxolitinibAT,
  title={Ruxolitinib: a targeted treatment option for patients with polycythemia vera},
  author={Kris Vaddi and Srdan Verstovsek and Jean Jacques Kiladjian},
  year={2016}
}
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Ruxolitinib: a targeted… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 119 REFERENCES

Impact of myeloproliferative neoplasms (MPNs) on patients’ overall health and productivity: results from the MPN LANDMARK SURVEY in the United States [abstract

R Mesa, CB Miller, M Thyne
  • Blood. 2014;124:abstract3183. (ASH Annual Meeting Abstracts)
  • 2014
VIEW 21 EXCERPTS
HIGHLY INFLUENTIAL

Cardiovascular events and intensity of treatment in polycythemia vera.

  • The New England journal of medicine
  • 2013
VIEW 21 EXCERPTS
HIGHLY INFLUENTIAL

Effect of ruxolitinib on markers of iron deficiency: an analysis of the RESPONSE trial

S Verstovsek, CN Harrison, J-J Kiladjian
  • Haematologica. 2015;100(s1):abstract672. (EHA Annual Meeting Abstracts)
  • 2015
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…